Executive Series 28 Jun 18: Actinogen Medical Ltd (ACW) CEO & Managing Director, Dr Bill Ketelbey
In this short video we discuss the:
• Company’s Phase II clinical trial for Xanamem, which if successful will be used in the treatment of Alzheimer’s disease.
• ACW’s recent placement of $15 million with cornerstone investment from leading USA biotech investor Biotechnology Value Fund.
• How the recently raised funds will be used to advance the Company’s development plan.
Click here to view video
To view more Executive Series interviews, visit:https://www.commsec.com.au/market-news/executive-series